Histogen Inc. Common Stock
HSTO
HSTO已於2023年10月4日下市。
關於： Histogen Inc is a clinical-stage therapeutics company focused on developing proprietary hypoxia-generated growth factor technology platforms and stem cell-free biologic products as potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. Under its biologics technology platform, the product candidates in development are HST-003, a treatment for joint cartilage repair, and HST-004, a treatment for spinal disc repair. It also has a pipeline of clinical and preclinical small molecule pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases that the company intends to develop.
員工： 7
新聞
我們尚未收到任何關於HSTO的最新新聞文章。